Cargando…

Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation

BACKGROUND: Post-market analyses revealed unanticipated links between first-generation Bruton’s tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension. Yet, whether this is seen with novel selective second (next)-generation BTKi therapy, acalabrutinib, is unknown. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Sunnia T., Azali, Leylah, Rosen, Lindsay, Zhao, Qiuhong, Wiczer, Tracy, Palettas, Marilly, Gambril, John, Kola-Kehinde, Onaopepo, Ruz, Patrick, Kalathoor, Sujay, Rogers, Kerry, Kittai, Adam, Grever, Michael, Awan, Farrukh, Byrd, John C., Woyach, Jennifer, Bhat, Seema A., Addison, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281099/ https://www.ncbi.nlm.nih.gov/pubmed/35836241 http://dx.doi.org/10.1186/s13045-022-01302-7

Ejemplares similares

Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review
por: Quartermaine, Cooper, et al.
Publicado: (2023)

Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia
por: Heerema, Nyla A., et al.
Publicado: (2020)

Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
por: Hyak, Jonathan M., et al.
Publicado: (2022)

Cardiovascular Event Reporting in Modern Cancer Radiation Therapy Trials
por: Prasad, Rahul N., et al.
Publicado: (2021)

Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
por: Mhibik, Maissa, et al.
Publicado: (2019)

P1696: ECONOMIC BURDEN IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR PATIENTS WITH ≥2 PRIOR LINES OF THERAPY INCLUDING A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I)
por: Priyadarshini, Masoom, et al.
Publicado: (2023)

Targeted Peripheral Nerve-directed Onabotulinumtoxin A Injection for Effective Long-term Therapy for Migraine Headache
por: Janis, Jeffrey E., et al.
Publicado: (2017)

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi
por: Zamprogna, Giulia, et al.
Publicado: (2023)

Identification of six hub genes in mantle cell lymphoma patients with BTKi resistance
por: Liu, Shuozi, et al.
Publicado: (2022)

Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i
por: Seymour, John F.
Publicado: (2022)

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL
por: Bryer, Emily, et al.
Publicado: (2022)

P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDY
por: Cohen, Jonathon, et al.
Publicado: (2023)

Clevidipine use after first-line treatment failure for perioperative hypertension in neurosurgical patients: A single-center experience
por: Borrell-Vega, Jaume, et al.
Publicado: (2020)

Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis
por: Brem, Elizabeth A., et al.
Publicado: (2022)

Immune response to COVID‐19 vaccination in patients with Waldenström macroglobulinaemia who pause their BTKi therapy
por: Rankin, Katherine, et al.
Publicado: (2023)

Timing of Postoperative Stroke and Risk of Mortality After Noncardiac Surgery: A Cohort Study
por: Mpody, Christian, et al.
Publicado: (2023)

Incidence of pathogenic, likely pathogenic, and uncertain ALS variants in a clinic cohort
por: Roggenbuck, Jennifer, et al.
Publicado: (2020)

D73. Multidisciplinary Approach to Cranioplasty - Outcomes from a 10-year Retrospective Study
por: Mitchell, Kerry-Ann S., et al.
Publicado: (2023)

Diversity in modern heart failure trials: Where are we, and where are we going
por: Anaba, Uzoma, et al.
Publicado: (2022)

An Ambulatory Care Clinic and Community Pharmacy Collaboration to Address Prescription Abandonment
por: Gaborcik, Joshua W., et al.
Publicado: (2019)

CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Poster: CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Perioperative do-not-resuscitate orders: Trainee experiential learning in preserving patient autonomy and knowledge of professional guidelines
por: Kushelev, Michael, et al.
Publicado: (2021)

Comparing the Efficacy of IV Ibuprofen and Ketorolac in the Management of Postoperative Pain Following Arthroscopic Knee Surgery. A Randomized Double-Blind Active Comparator Pilot Study
por: Uribe, Alberto A., et al.
Publicado: (2018)

P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES
por: Woyach, Jennifer, et al.
Publicado: (2023)

P592: SINGLE-CELL RNA SEQUENCING REVEALS THE SPATIAL HETEROGENEITY OF EXHAUSTED T CELLS IN BTKI-RESISTANT RICHTER TRANSFORMATION PATIENTS
por: Sha, Yeqin, et al.
Publicado: (2023)

Post-Cesarean Delivery Analgesic Outcomes in Patients Maintained on Methadone and Buprenorphine: A Retrospective Investigation
por: Reno, Joseph L, et al.
Publicado: (2020)

Application of Nonfungible Tokens to Health Care. Comment on “Blockchain Technology Projects to Provide Telemedical Services: Systematic Review”
por: Gambril, John, et al.
Publicado: (2022)

The effect of supplemental high Fidelity simulation training in medical students
por: Meyers, Lori, et al.
Publicado: (2020)

Phasic Diastolic Coronary Artery Compression: A Rare Cause of Chest Pain at Rest
por: Gambril, John A, et al.
Publicado: (2023)

Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
por: Sardesai, Sagar, et al.
Publicado: (2020)

Snoring-Induced Vibratory Angioedema
por: Kalathoor, Ipe
Publicado: (2015)

Amyotrophic Lateral Sclerosis Genetic Access Program: Paving the Way for Genetic Characterization of ALS in the Clinic
por: Roggenbuck, Jennifer, et al.
Publicado: (2021)

Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy
por: Yano, Max, et al.
Publicado: (2022)

The Numerous Benefits of Social Media for Medicine. Comment on “Documenting Social Media Engagement as Scholarship: A New Model for Assessing Academic Accomplishment for the Health Professions”
por: Gambril, John Alan, et al.
Publicado: (2021)

Risk Factors for Tumor Lysis Syndrome in patients with Chronic Lymphocytic Leukemia Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol
por: Blum, Kristie A., et al.
Publicado: (2011)

Bortezomib‐based therapy is effective and well tolerated in frontline and multiply pre‐treated Waldenström macroglobulinaemia including BTKi failures: A real‐world analysis
por: Khwaja, Jahanzaib, et al.
Publicado: (2022)

Impact of Targeted Therapy on Outcome of Chronic Lymphocytic Leukemia Patients with Relapsed Del(17p13.1) Karyotype at a Single Center
por: Stephens, Deborah M., et al.
Publicado: (2014)

P1006: CHARACTERIZATION OF TL-895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF)
por: Gulrajani, Michael, et al.
Publicado: (2023)

A prospective observational cohort study to evaluate patients’ experience during sequential cataract surgery under monitored anesthesia care and topical anesthesia
por: Heard, Jarrett A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8mk4qbu37hdqq9qca7tel6n3qf